@Tooheys8
Happy to be corrected, I suspect it is basically because it provides 'immediate access' to a much larger patient 'data-set' to move the 'breadth' of the testing/assessments forward far more quickly than waiting (and paying) for access to 'fresh' new-samples as they become available...
Reading between the lines, it seems exosomes have a 'shelf-life' as such, so will basically required UQ & IIQ to 'revert' to basically acquiring access to 'fresh samples' on an ongoing basis to move the test forward (get 'statistical runs' on the board with a significant sample size), collate and then, present to industry, hence the H2FY24 delay-statement...
ML
Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY, page-13
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.025(4.81%) |
Mkt cap ! $50.15M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.5¢ | 53.0¢ | $30.32K | 56.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9533 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 1956 | 1 |
View Market Depth
| Last trade - 14.28pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
54.0¢ |
Change
0.025 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| 54.0¢ | 54.0¢ | 54.0¢ | 1244 | ||
| Last updated 14.12pm 14/05/2024 ? | |||||
| IIQ (ASX) Chart |